AN2 Therapeutics develops small-molecule medicines from boron chemistry for infectious diseases, hematologic disorders, and oncology.
AN2 Therapeutics has raised $40.0M in total funding. The most recent round was Grant. The last funding was announced in September 2026.
AN2 Therapeutics's investors include RA Capital Management, Vivo Capital, TCG Crossover, Janus Henderson Investors, Bill & Melinda Gates Foundation.
AN2 Therapeutics is headquartered in Menlo Park, United States.
AN2 Therapeutics develops small-molecule medicines from boron chemistry for infectious diseases, hematologic disorders, and oncology.
AN2 Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AN2 Therapeutics — Funding & Investors." VCBacked, September 28, 2026, https://www.vcbacked.co/company/an2-therapeutics. Accessed November 13, 2026.
VCBacked. (2026). AN2 Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/an2-therapeutics
{{cite web |title=AN2 Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/an2-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at AN2 Therapeutics? Request a listing update